Oluyemi Okupe Sells 9,388 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,388 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $27.89, for a total transaction of $261,831.32. Following the completion of the sale, the chief financial officer owned 264,117 shares of the company’s stock, valued at approximately $7,366,223.13. This represents a 3.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.09, for a total transaction of $1,943,389.47.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $31.03 on Thursday. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The company has a market capitalization of $7.24 billion, a P/E ratio of -49.25 and a beta of 2.40. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $65.30. The stock has a 50 day moving average of $32.17 and a 200-day moving average of $26.05.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the prior year, the business earned $0.17 EPS. The company’s revenue for the quarter was up 38.2% compared to the same quarter last year. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Versant Capital Management Inc grew its stake in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after buying an additional 319 shares in the last quarter. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Bogart Wealth LLC lifted its stake in Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health in the first quarter valued at about $30,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations regarding patient-data sharing, advertising and subscription practices, arguing that the agency misunderstands Hims & Hers’ business model. His comments may have helped ease some investor concerns. Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
• Positive Sentiment: Management continues to highlight growth opportunities, including an AI health coach that could improve medication adherence, expanded patient access and the transition toward branded GLP-1 treatments. These initiatives support the company’s longer-term growth narrative. Hims & Hers CEO discusses AI health coach
• Positive Sentiment: An analyst report described the Eucalyptus transaction as a potential avenue for entering new markets and broadening Hims & Hers’ international reach. Hims & Hers: Eucalyptus Deal Unlocks New Markets
• Neutral Sentiment: Multiple insider dispositions were reported, including sales by the CEO, CFO and other executives. Most involved shares withheld or sold under pre-arranged plans to cover taxes on vested equity awards, making them weaker signals of management’s outlook than discretionary selling. Hims & Hers insider transactions
• Negative Sentiment: The FTC lawsuit remains the central risk, with allegations involving privacy practices, advertising, billing and difficult subscription cancellations. The litigation has also prompted investigations by Kaplan Fox, Berger Montague, Kessler Topaz and other shareholder law firms, raising potential compliance, reputational and securities-liability concerns. Berger Montague investigation
• Negative Sentiment: Although quarterly revenue exceeded expectations and rose strongly year over year, Hims & Hers reported a substantially larger-than-expected loss. Continued questions about profitability and the GLP-1 strategy could limit the stock’s recovery. Questions from the Hims & Hers earnings call

Wall Street Analyst Weigh In

Several brokerages recently commented on HIMS. Bank of America lifted their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. TD Cowen raised their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Citigroup reduced their price objective on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. dropped their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.